An Oncology biotech pioneering  RAD51 inhibition to treat high replication stress tumors

Satya Pharma Innovations

Flagship program - RAD51:BRCA2 Disruptor

Potential foundational drug across all high replication stress tumors

RAD51 is the central recombinase involved in homologous-mediated DNA double strand break repair, downstream of PARP, ATR, ATM, and CHK1/2. The centrality and functionality of RAD51 in the DDR pathway confers upon it a broad role in various replication stress-induced cancers. Unlike precision oncology drugs, targeted RAD51:BRCA2 disruptors are pan-cancer drugs to treat a wide range of solid tumors with innate or induced high replication stress.

Satya’s candidate-stage, first-in-class RAD51:BRCA2 inhibitor is an orally available small molecule compound with a biochemical potency of 2 nM, cellular potency of 20 nM, direct PD (RAD51 nuclear foci reduction) at 100 nM and is functionally active across a range of cells with high replication stress, such as KRAS, EGFR and PI3K driven tumors. 

It also combines well with replication stress inducers such PARPi, chemo & other DDR/ cell cycle inhibitors

Satya Pharma Innovations

Flagship program - RAD51:BRCA2 Disruption

Potential foundational drug across all high replication stress tumors

RAD51 is the central recombinase involved in homologous-mediated DNA double strand break repair, downstream of PARP, ATR, ATM, and CHK1/2. The centrality and functionality of RAD51 in the DDR pathway confers upon it a broad role in various replication stress-induced cancers. Unlike precision oncology drugs, targeted RAD51:BRCA2 disruptors are pan-cancer drugs to treat a wide range of solid tumors with innate or induced high replication stress.

Satya’s candidate-stage, first-in-class RAD51:BRCA2 inhibitor is an orally available small molecule compound with a biochemical potency of 2 nM, cellular potency of 20 nM, direct PD (RAD51 nuclear foci reduction) at 100 nM and is functionally active across a range of cells with high replication stress, such as KRAS, EGFR and PI3K driven tumors. 

It also combines well with replication stress inducers such PARPi, chemo & other DDR/ cell cycle inhibitors

Science

Satya is a pre-clinical stage targeted oncology company, building a portfolio of first-in-class and best-in-class therapeutics in the DDR space.

An additional key focus area is targets with potential pan-cancer applications.

We have pioneered targeting of RAD51:BRCA2 interactions as a druggable mechanism to treat a variety of high replication stress tumors.

Satya has a world-class scientific and executive team with a successful past track record of translating 75 research programs to over 15 clinical candidates across oncology and inflammatory disorders.

Science

Satya is a pre-clinical stage targeted oncology company, building a portfolio of first-in-class and best-in-class therapeutics in the DDR space. An additional key focus area is targets with potential pan-cancer applications. We have pioneered targeting of RAD51:BRCA2 interactions as a druggable mechanism to treat a variety of high replication stress tumors. Satya has a world-class scientific and executive team with a successful past track record of translating 75 research programs to over 15 clinical candidates across oncology and inflammatory disorders.

Advisory Board

Satya’s Scientific Advisory Board comprises seasoned and accomplished
scientists, with preclinical and clinical expertise in oncology.
Satya’s Scientific Advisory Board comprises seasoned and accomplished scientists, with preclinical and clinical expertise in oncology.

Pipeline

Satya’s Pipeline comprises First-In-Class and Best-In-Class
Targets focused on DDR pathway and Oncogenes.

TARGET

MOA / INDICATION

BIO MARKER

RIGHTS

EARLY DISCOVERY

LEAD OPTIMIZATION

PRE - CLINICAL

IND

RAD51

DDR; TNBC, NSCLC, PAN Ca

Replication Stress, Oncogene mutations

Global

87%

SOS1

Oncogene; NSCLC, CRC

EGFR mutation & Pan RAS mutation

Global

76%

Undisclosed

DDR/Oncogene

Undisclosed

Partnered

Undisclosed

KIF18A

DDR

CIN+ve cells

Global

49%

PARG

DDR

HRD

Global

35%

USP1

DDR

HRD

Global

9%

Pipeline

Satya’s Pipeline comprises First-In-Class and Best-In-Class
Targets focused on DDR pathway and Oncogenes.
Satya’s Pipeline comprises First-In-Class and Best-In-Class Targets focused on DDR pathway and Oncogenes.

TARGET

MOA / INDICATION

BIO MARKER

RIGHTS

EARLY DISCOVERY

LEAD OPTIMIZATION

PRE - CLINICAL

IND

RAD51

DDR; TNBC, NSCLC, PAN Ca

Replication Stress, Oncogene mutations

Global

91%

SOS1

Oncogene; NSCLC, CRC

EGFR mutation & Pan RAS mutation

Global

77%

Undisclosed

DDR/Oncogene

Undisclosed

Partnered

Undisclosed

KIF18A

DDR

CIN+ve cells

Global

49%

PARG

DDR

HRD

Global

35%

USP1

DDR

HRD

Global

11%

Pipeline

Satya’s Pipeline comprises First-In-Class and Best-In-Class Targets focused on DDR pathway and Oncogenes.

Recent highlights on our programs, News, Events and Leadership

Scroll to Top

Murthy Chavali

Founder and CEO

Prior to starting Satya, CSN was CEO of Aurigene between 2005-19. During this period, Aurigene was turned around into a profitable company, and led through transformational changes to become a highly valued discovery and clinical development organization, with a pipeline of own assets and multiple partnered programs. These include small-molecule Immuno-oncology assets targeting PD-L1 and CD47, kinase inhibitor programs including FGFR, IRAK4, CDK7 and an anti-inflammatory program, targeting RoRgt. A pre-clinical pipeline of other assets including protein degraders has been developed during this time.

Previously, CSN was COO of Gland Pharma Limited. Gland Pharma received the first FDA approval for an injectable facility in India.

CSN started his career with ICICI Ventures, India’s first VC fund. CSN also started and led a boutique Investment Bank focused on the Life Sciences industry. He is a Chemical Engineer from IIT Madras, and an MBA from IIM, Bangalore

He is an independent Director on the boards of Gland Pharma Limited (NSE: GLAND), Balaji Amines Limited (NSE: BALAMINES) and Vijaya Diagnostic Centre Limited.

Murthy Chavali

Founder and CEO

Prior to starting Satya, CSN was CEO of Aurigene between 2005-19. During this period, Aurigene was turned around into a profitable company, and led through transformational changes to become a highly valued discovery and clinical development organization, with a pipeline of own assets and multiple partnered programs. These include small-molecule Immuno-oncology assets targeting PD-L1 and CD47, kinase inhibitor programs including FGFR, IRAK4, CDK7 and an anti-inflammatory program, targeting RoRgt. A pre-clinical pipeline of other assets including protein degraders has been developed during this time.

Previously, CSN was COO of Gland Pharma Limited. Gland Pharma received the first FDA approval for an injectable facility in India.

CSN started his career with ICICI Ventures, India’s first VC fund. CSN also started and led a boutique Investment Bank focused on the Life Sciences industry. He is a Chemical Engineer from IIT Madras, and an MBA from IIM, Bangalore

He is an independent Director on the boards of Gland Pharma Limited (NSE: GLAND), Balaji Amines Limited (NSE: BALAMINES) and Vijaya Diagnostic Centre Limited.

Srikant Viswanadha

phd

Chief Scientific Officer

Discovery to clinical development expertise across multiple projects

  • Over 19 years of Pharma experience, having worked on/ led 7 projects from Discovery to Clinical Development

  • MS (Idaho), PhD (Virginia Tech), Post-doc (NIH, Bethesda)

  • Previously worked with Glenmark and Incozen/ Rhizen, last as Chief Scientific Officer at Rhizen

Srikant Viswanadha

phd

Chief Scientific Officer

Discovery to clinical development expertise across multiple projects

  • Over 19 years of Pharma experience, having worked on/ led 7 projects from Discovery to Clinical Development

  • MS (Idaho), PhD (Virginia Tech), Post-doc (NIH, Bethesda)

  • Previously worked with Glenmark and Incozen/ Rhizen, last as Chief Scientific Officer at Rhizen

sukanya patra

phd

Director, Discovery Biology

Discovery biology and target validation expertise

Sukanya has over 16 years of research experience, including over 10 years in industry.

Ph.D., University of California San Diego (UCSD) and San Diego State University (SDSU); M.Pharm., Jadavpur University, India

She has participated and led multiple programs particularly focused in oncology and immune-oncology, starting from critical target evaluation, strategic differentiation, assay development, design of appropriate screening cascades, candidate identification and profiling, across many programs.

She has been formerly Principal Scientist at Lupin, and closely involved in programs that have since reached clinical development. Along with a brilliant academic career, Sukanya has been the recipient of various awards for her outstanding contributions as a scientist through her career

sukanya patra

phd

Director, Discovery Biology

Discovery biology and target validation expertise

Sukanya has over 16 years of research experience, including over 10 years in industry.

Ph.D., University of California San Diego (UCSD) and San Diego State University (SDSU); M.Pharm., Jadavpur University, India

She has participated and led multiple programs particularly focused in oncology and immune-oncology, starting from critical target evaluation, strategic differentiation, assay development, design of appropriate screening cascades, candidate identification and profiling, across many programs.

She has been formerly Principal Scientist at Lupin, and closely involved in programs that have since reached clinical development. Along with a brilliant academic career, Sukanya has been the recipient of various awards for her outstanding contributions as a scientist through her career

Navnath Karche

phd

Director, Medicinal Chemistry

Small Molecule discovery expertise across multiple therapeutic areas

Over 18 years in drug discovery, with multiple programs across Oncology, Metabolic Disorders & CNS

PhD, Pune India and Post-doc, Rouen, France

Previously at Dai-ichi and Lupin

Over 18 patents and 9 publications

Navnath Karche

phd

Director, Medicinal Chemistry

Small Molecule discovery expertise across multiple therapeutic areas

Over 18 years in drug discovery, with multiple programs across Oncology, Metabolic Disorders & CNS

PhD, Pune India and Post-doc, Rouen, France

Previously at Dai-ichi and Lupin

Over 18 patents and 9 publications

Ali Fattaey

phd

Advisor, Science And Strategy

Seasoned Biotech Professional with >25 years in the Industry

CEO, MetaboMed

Seasoned Biotech professional, with over 25 years in industry including as CXO/ Founder VP – Research at Onyx (1994-2001), among early scientists at Onyx

PhD, Kansas and Post-doc, Harvard

Ali Fattaey

phd

Advisor, Science And Strategy

Seasoned Biotech Professional with >25 years in the Industry

CEO, MetaboMed

Seasoned Biotech professional, with over 25 years in industry including as CXO/ Founder VP – Research at Onyx (1994-2001), among early scientists at Onyx

PhD, Kansas and Post-doc, Harvard

John Bondo Hansen

phd

Advisor, Discovery Chemistry

Over 35 years in pharma and biotech

Worked in drug discovery at Ferrosan, Denmark and Novo Nordisk, Denmark in positions of increasing responsibility, ending as vice president of medicinal chemistry at Novo Nordisk.

From 2008 worked in biotech. Co-founder and member of management of several companies including Contera Pharma, which was acquired by Bukwang Pharma of Korea in 2014.

Board member, Aurigene, India from 2008 to 2013 Author and co-author of 77 peer-reviewed publications. Inventor or co-inventor of more than 50 published patents and patent applications.

PhD in Medicinal chemistry from University of Copenhagen, Denmark and Post-doc, Texas A&M University, USA.

John Bondo Hansen

phd

Advisor, Discovery Chemistry

Over 35 years in pharma and biotech

Worked in drug discovery at Ferrosan, Denmark and Novo Nordisk, Denmark in positions of increasing responsibility, ending as vice president of medicinal chemistry at Novo Nordisk.

From 2008 worked in biotech. Co-founder and member of management of several companies including Contera Pharma, which was acquired by Bukwang Pharma of Korea in 2014.

Board member, Aurigene, India from 2008 to 2013 Author and co-author of 77 peer-reviewed publications. Inventor or co-inventor of more than 50 published patents and patent applications.

PhD in Medicinal chemistry from University of Copenhagen, Denmark and Post-doc, Texas A&M University, USA.